{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:31:49Z","timestamp":1784950309708,"version":"3.55.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["12\/0007"],"award-info":[{"award-number":["12\/0007"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000182","name":"DOD | United States Army | Medical Research and Materiel Command","doi-asserted-by":"publisher","award":["W81XWH-10-2-0059"],"award-info":[{"award-number":["W81XWH-10-2-0059"]}],"id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000182","name":"DOD | United States Army | Medical Research and Materiel Command","doi-asserted-by":"publisher","award":["WX81XWH-13-2-0026"],"award-info":[{"award-number":["WX81XWH-13-2-0026"]}],"id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) are at risk for developing hemolytic anemia when given the antimalarial drug primaquine (PQ). The WHO Evidence Review Group released a report suggesting that mass administration of a single dose of PQ at 0.25 mg of base\/kg of body weight (mpk) (mouse equivalent of 3.125 mpk) could potentially reduce malaria transmission based on its gametocytocidal activity and could be safely administered to G6PD-deficient individuals, but there are limited safety data available confirming the optimum single dose of PQ. A single-dose administration of PQ was therefore assessed in our huRBC-SCID mouse model used to predict hemolytic toxicity with respect to G6PD deficiency. In this model, nonobese diabetic (NOD)\/SCID mice are engrafted with human red blood cells (huRBC) from donors with the African or Mediterranean variant of G6PDd (A-G6PDd or Med-G6PDd, respectively) and demonstrate dose-dependent sensitivity to PQ. In mice engrafted with A-G6PD-deficient huRBC, single-dose PQ at 3.125, 6.25, or 12.5 mpk had no significant loss of huRBC compared to the vehicle control group. In contrast, in mice engrafted with Med-G6PDd huRBC, a single dose of PQ at 3.125, 6.25, or 12.5 mpk resulted in a significant, dose-dependent loss of huRBC compared to the value for the vehicle control group. Our data suggest that administration of a single low dose of 0.25 mpk of PQ could induce hemolytic anemia in Med-G6PDd individuals but that use of single-dose PQ at 0.25 mpk as a gametocytocidal drug to block transmission would be safe in areas where A-G6PDd predominates.<\/jats:p>","DOI":"10.1128\/aac.00600-16","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T02:33:19Z","timestamp":1469500399000},"page":"5906-5913","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Single-Dose Primaquine in a Preclinical Model of Glucose-6-Phosphate Dehydrogenase Deficiency: Implications for Use in Malaria Transmission-Blocking Programs"],"prefix":"10.1128","volume":"60","author":[{"given":"Kristina S.","family":"Wickham","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Baresel","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1988-6185","authenticated-orcid":false,"given":"Sean R.","family":"Marcsisin","sequence":"additional","affiliation":[{"name":"Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sousa","sequence":"additional","affiliation":[{"name":"Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau T.","family":"Vuong","sequence":"additional","affiliation":[{"name":"Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Reichard","sequence":"additional","affiliation":[{"name":"Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Campo","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu L.","family":"Tekwani","sequence":"additional","affiliation":[{"name":"National Center for Natural Products Research and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Walker","sequence":"additional","affiliation":[{"name":"National Center for Natural Products Research and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Rochford","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"WHO. 2014. World malaria report 2014. WHO Geneva Switzerland. http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2014\/report\/en\/."},{"key":"e_1_3_2_3_2","first-page":"625","article-title":"Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum","volume":"38","author":"Rieckmann KH","year":"1968","unstructured":"Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD. 1968. Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ 38:625\u2013632.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_2_4_2","first-page":"CD008152","article-title":"Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission","volume":"2","author":"Graves PM","year":"2015","unstructured":"Graves PM, Gelband H, Garner P. 2015. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 2:CD008152.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0254"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1179\/2047773215Y.0000000016"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004664"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.11.3613.bloodjournal84113613"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60073-2"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-418"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70288-3"},{"key":"e_1_3_2_13_2","volume-title":"The safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide","author":"WHO Evidence Review Group","year":"2012","unstructured":"WHO Evidence Review Group. 2012. The safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide. WHO, Geneva, Switzerland. http:\/\/www.who.int\/malaria\/mpac\/sep2012\/primaquine_single_dose_pf_erg_meeting_report_aug2012.pdf."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-424"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70268-8"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02889-14"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-407826-0.00004-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1310402110"},{"key":"e_1_3_2_19_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.","edition":"8"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9574LSF"},{"key":"e_1_3_2_21_2","volume-title":"Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","author":"Center for Drug Evaluation and Research","year":"2005","unstructured":"Center for Drug Evaluation and Research. 2005. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. US Department of Health and Human Services and US Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/downloads\/Drugs\/.\/Guidances\/UCM078932.pdf."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02369.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-259"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00015-15"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-141"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis959"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.779"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040066"},{"key":"e_1_3_2_29_2","first-page":"1277","article-title":"Diagnosis and management of G6PD deficiency","volume":"72","author":"Frank JE","year":"2005","unstructured":"Frank JE. 2005. Diagnosis and management of G6PD deficiency. Am Fam Physician 72:1277\u20131282.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0441-1"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.12-0025"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2014.948421"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0714-3"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00600-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00600-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:05:25Z","timestamp":1645484725000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00600-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1128\/AAC.00600-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00600-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"2016-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}